Oak Ridge Investments LLC Sells 1,509 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Oak Ridge Investments LLC decreased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 38,869 shares of the biopharmaceutical company’s stock after selling 1,509 shares during the period. Oak Ridge Investments LLC’s holdings in Agios Pharmaceuticals were worth $1,277,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AGIO. Farallon Capital Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after acquiring an additional 63,900 shares during the period. State Street Corp increased its position in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares in the last quarter. Erste Asset Management GmbH bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $97,199,000. Geode Capital Management LLC boosted its position in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after buying an additional 6,101 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after buying an additional 855,739 shares during the last quarter.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Trading Up 1.9 %

Agios Pharmaceuticals stock opened at $32.42 on Friday. The company has a market cap of $1.85 billion, a PE ratio of 2.85 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The company’s 50-day moving average is $44.72 and its two-hundred day moving average is $45.07.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.